Skip to content

Pelvic Drain After Rectal Resection for Mid-low Rectal Cancer

Pelvic Drain After Rectal Resection for Mid-low Rectal Cancer: a Randomised Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04573621
Acronym
GECO1
Enrollment
518
Registered
2020-10-05
Start date
2020-10-31
Completion date
2022-09-30
Last updated
2020-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer

Brief summary

This RCT aims at assessing the effects of a pelvic drain after total mesorectal excision for mid-low rectal cancer on the rates of pelvic sepsis and anastomotic leaks.

Detailed description

This is a 2-arm, non-inferiority RCT. Patients undergoing total mesorectal excision for mid-low rectal cancer will be randomly assigned into two groups: * pelvic drain * no pelvic drain. Patients will be followed-up to assess the rates of anastomotic leaks, pelvic sepsis and secondary outcomes.

Interventions

PROCEDUREPelvic drain

A pelvic drain is placed

OTHERNo pelvic drain is placed

A pelvic drain is not placed

Sponsors

Hospital Universitari Vall d'Hebron Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Masking description

The assessor will not know whether the patient received a drain or not

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or Female, 18 year-of-age or above * Mid or low rectal cancer * Anastomosis below the peritoneal reflection * Total mesorectal excision (TME) * Capability to understand the study * Informed consent

Exclusion criteria

* For women, pregnancy * Chronic kidney failure or hepatic failure, immunodepression, malnoutrition * Life expectancy \< 6 months * Partial mesorectal excision * Abdominoperineal excision * Multivisceral resections * Emergency surgery

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with pelvic sepsis0-30 days postoperativelyanastomotic leak or pelvic collections clinically or radiologically detected

Secondary

MeasureTime frameDescription
Length of postperative stay0-30 days postoperatively or until dischargeDays of stay after surgery
Number of participants with postoperative ileus0-30 days postoperativelyPostoperative ileus
Management of pelvic sepsis0-30 days postoperativelyType of management (medical, rediological, surgical)
Postoperative complications0-30 days postoperativelyOverall postoperative complications
CT scan or imaging needed0-30 days postoperativelyNecessity of performing unscheduled imaging tests
Diagnostic delay for a leak0-30 days postoperativelyDays between surgery and leak detection
Stoma presence at 1-year follow-up12 months after surgeryNecessity of maintaining the diverting ileostomy at 1-year follow-up
Late pelvic collectionsup to 60 days after surgeryPresence of pelvic collections detected at longer follow-up intervals
Small bowel obstructionup to 60 days after surgeryMechanical small bowel obstruction
Quality of life associated with a drain30 days postoperativelyVisual Analogue Scale 0-10 (higher score means better outcome) score of postoperative pain and wound complaints
Any complications associated with drain removal after surgeryup to 60 days after surgerySafety of drain removal after surgery
Time to flatus and bowel movement0-30 days postoperativelyDays between surgery and flatus/faeces

Countries

Spain

Contacts

Primary ContactEloy Espín-Basany
eespin@vhebron.net932746000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026